Nodthera Limited

Other

David Harrison

Alan Paul Watt

Mark G Bock

Oleksandr Levenets

Rehab Al-Jamal

Michal Galezowski

Charles-Henry Fabritius

Grzegorz Witold Topolnicki

Roderick Alan Porter

Charles-Henry Robert Yves Fabritius

Nicolas Boutard

Piotr Kowalczyk

Jakub Woyciechowski

Jane E Scanlon

Nicolas Felix Pierre Boutard

The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.

Sulphonyl urea derivatives as NLRP3 inflammasome modulators

The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as autoinflammatory and autoimmune diseases and cancers.

Selective inhibitors of NLRP3 inflammasome

The present disclosure relates to compounds of Formula (I) and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.

Sulfonylurea derivatives and uses thereof

The present disclosure relates to compounds of Formula (I): and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein inhibit the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inter alia autoinflammatory and autoimmune diseases and cancers. 

Urea derivatives and methods of use thereof

The present invention methods and novel compounds for facilitating tissue repair and regeneration when the extracellular matrix is damaged. Specifically, binding of the beta 1 integrin is shown to provide a modulation of its functional activity resulting in up regulation of extracellular matrix anabolism. The invention therefore provides a method and novel compounds which can facilitate tissue regeneration in many systems such as the lung, skin, liver and bone. In particular, the binding of the JB1a antibody to a site of amino acid residues 82 to 87 of the mature beta 1 integrin is shown to be particularly effective in mediating the described tissue repair effect.

Tissue repair by modulation of beta-1 integrin biological function

The present invention provides methods and compositions which modulate beta 1 integrin activity by functioning as allosteric antagonists. In particular, the present invention provides methods for mediating tissue repair where insult or injury has occurred by antagonising the allosteric function of beta 1 integrin.

Growing community of inventors

Edinburgh, United Kingdom

David Harrison